Suven Pharmaceuticals Past Earnings Performance
Past criteria checks 3/6
Suven Pharmaceuticals has been growing earnings at an average annual rate of 8.5%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 11.4% per year. Suven Pharmaceuticals's return on equity is 18.7%, and it has net margins of 31.8%.
Key information
8.5%
Earnings growth rate
8.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.4% |
| Return on equity | 18.7% |
| Net Margin | 31.8% |
| Next Earnings Update | 15 May 2024 |
Recent past performance updates
Recent updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08Revenue & Expenses BreakdownBeta
How Suven Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 11,678 | 3,709 | 1,158 | 109 |
| 30 Sep 23 | 13,017 | 4,318 | 1,126 | 108 |
| 30 Jun 23 | 13,491 | 4,243 | 1,127 | 84 |
| 31 Mar 23 | 13,403 | 4,113 | 1,105 | 86 |
| 31 Dec 22 | 13,348 | 3,790 | 1,179 | 87 |
| 30 Sep 22 | 13,726 | 4,313 | 1,133 | 86 |
| 30 Jun 22 | 13,952 | 4,563 | 1,078 | 102 |
| 31 Mar 22 | 13,202 | 4,538 | 1,024 | 104 |
| 31 Dec 21 | 12,155 | 4,453 | 881 | 97 |
| 30 Sep 21 | 10,989 | 3,988 | 844 | 102 |
| 30 Jun 21 | 10,353 | 3,759 | 821 | 103 |
| 31 Mar 21 | 10,097 | 3,623 | 784 | 111 |
| 31 Dec 20 | 9,353 | 3,534 | 934 | -12 |
| 30 Sep 20 | 8,391 | 2,977 | 874 | -11 |
| 30 Jun 20 | 8,746 | 3,166 | 818 | 3 |
| 31 Mar 20 | 8,338 | 3,170 | 695 | 141 |
| 31 Mar 19 | 9,068 | 2,623 | 814 | 0 |
Quality Earnings: SUVENPHAR has high quality earnings.
Growing Profit Margin: SUVENPHAR's current net profit margins (31.8%) are higher than last year (28.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SUVENPHAR's earnings have grown by 8.5% per year over the past 5 years.
Accelerating Growth: SUVENPHAR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: SUVENPHAR had negative earnings growth (-2.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (23.3%).
Return on Equity
High ROE: SUVENPHAR's Return on Equity (18.7%) is considered low.